Human CD30 Ligand/TNFSF8 APC-conjugated Antibody
Human CD30 Ligand/TNFSF8 APC-conjugated Antibody Summary
Accession # P32971
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Detection of CD30 Ligand/TNFSF8 in Human PBMCs by Flow Cytometry. Human peripheral blood mononuclear cells (PBMCs) treated with 50 ng/mL PMA and 200 ng/mL Calcium Ionomycin overnight were stained with Mouse Anti-Human CD3e PE-conjugated Monoclonal Antibody (Catalog # FAB100P) and either (A) Mouse Anti-Human CD30 Ligand/TNFSF8 APC-conjugated Monoclonal Antibody (Catalog # FAB1028A) or (B) Mouse IgG2BAllophycocyanin Isotype Control (Catalog # IC0041A). View our protocol for Staining Membrane-associated Proteins.
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: CD30 Ligand/TNFSF8
CD30 ligand (CD30L)/TNFSF8 is a type II membrane protein belonging to the TNF superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. The protein is also constitutively expressed on granulocytes and medullary thymic epithelial cells. The specific receptor for CD30L is CD30/TNFRSF8, a type I transmembrane glycoprotein belonging to the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkin's and Reed-Sternberg cells using the monoclonal antibody Ki-1. CD30 is also expressed on different non-Hodgkin's lymphomas, virus-infected T and B cells, and on normal T and B cells after activation. Among T cells, CD30 is preferentially expressed on a subset of T cells producing Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and IL-4 receptor. CD30 ligation by CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation and cell death by apoptosis. CD30 can act as a costimulatory molecule in thymic negative selection and may also play a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas. Human and mouse CD30 ligand cDNAs share 70% sequence homology.
- Brunangelo, F. et al. (1995) Blood 85:1.
- Gruss, H.-J. and F. Herrmann (1996) Leukemia and Lymphoma 20:397.
- Chiarle, R. et al. (1999) J. Immunol. 163:194.
Citation for Human CD30 Ligand/TNFSF8 APC-conjugated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30- Tumors
Authors: AA Hombach, G Rappl, H Abken
Mol. Ther., 2019-06-19;0(0):.
Sample Types: Whole Cells
Applications: Flow Cytometry
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human CD30 Ligand/TNFSF8 APC-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human CD30 Ligand/TNFSF8 APC-conjugated Antibody and earn rewards!
Have you used Human CD30 Ligand/TNFSF8 APC-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image